Lipids and secondary prevention of ischaemic heart disease - Lipid lowering treatment is now indicated for patients with ''normal'' cholesterol concentrations

被引：0
|
作者：
Byrne, CD
Wild, SH
机构：
[1] UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT MED, CAMBRIDGE CB2 2QR, ENGLAND
[2] UNIV LONDON LONDON SCH HYG & TROP MED, EPIDEMIOL UNIT, LONDON WC1E 7HT, ENGLAND
来源：
BMJ-BRITISH MEDICAL JOURNAL | 1996年 / 313卷 / 7068期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1273 / 1274
页数：2
相关论文
共 50 条
  • [41] Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: New evidence, implications and outstanding issues
    Watts, GF
    Burke, V
    CURRENT OPINION IN LIPIDOLOGY, 1996, 7 (06) : 341 - 355
  • [42] EFFECT OF ATROMID-S ON FIBRINOLYTIC ACTIVITY IN PATIENTS WITH ISCHAEMIC HEART DISEASE AND NORMAL BLOOD CHOLESTEROL LEVELS
    GOODHART, JM
    DEWAR, HA
    BMJ-BRITISH MEDICAL JOURNAL, 1966, 1 (5483): : 325 - +
  • [43] LIPID CONTROL AND USE OF LIPID-LOWERING DRUGS FOR SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS IN TAIWAN: THE TAIWANESE SECONDARY PREVENTION FOR PATIENTS WITH ATHEROSCLEROTIC DISEASE (T-SPARCLE) REGISTRY
    Yin, Wei-Hsian
    Yin, Wei-Hsian
    HEART, 2012, 98 : E10 - E11
  • [44] Trends in secondary prevention of ischaemic heart disease in the UK 1994-2005: use of individual and combination treatment
    DeWilde, S.
    Carey, I. M.
    Richards, N.
    Whincup, P. H.
    Cook, D. G.
    HEART, 2008, 94 (01) : 83 - 88
  • [45] Quality of lipid-lowering therapy in patients with known ischaemic heart disease. A register based study in 3477 subjects
    Kanstrup, H
    Lassen, JF
    Heickendorff, L
    Larsen, ML
    EUROPEAN HEART JOURNAL, 2001, 22 : 494 - 494
  • [46] Efficacy of a nurse-led lipid-lowering secondary prevention intervention in patients hospitalized for ischemic heart disease: A pilot randomized controlled trial
    Ruiz-Bustillo, Sonia
    Ivern, Consol
    Badosa, Neus
    Farre, Nuria
    Marco, Esther
    Bruguera, Jordi
    Cladellas, Merce
    Enjuanes, Cristina
    Cainzos-Achirica, Miguel
    Marti-Almor, Julio
    Comin-Colet, Josep
    EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2019, 18 (05) : 366 - 374
  • [47] Regression of coronary atherosclerosis in patients with coronary artery disease and normal cholesterol by intensive lipid-lowering therapy with pravastatin
    Ueno, T
    Ikeda, H
    Ueyama, T
    Eguchi, H
    Kato, A
    Mori, E
    Ichiki, K
    Hashino, T
    Haramaki, N
    Imaizumi, T
    CIRCULATION, 1997, 96 (08) : 2202 - 2202
  • [48] SECONDARY PREVENTION USING CHOLESTEROL-LOWERING MEDICATIONS IN PATIENTS MEETING NEW TREATMENT GUIDELINES: A RETROSPECTIVE COHORT ANALYSIS
    Han, X.
    McCombs, J. S.
    Fox, D. S.
    Chu, M.
    Dougherty, J. S.
    VALUE IN HEALTH, 2018, 21 : S6 - S6
  • [49] Secondary prevention of heart disease amongst patients with lipid abnormalities: Practice and trends in the United States
    Brown, BG
    Zhao, XQ
    Bardsley, J
    Albers, JJ
    JOURNAL OF INTERNAL MEDICINE, 1997, 241 (04) : 283 - 294
  • [50] INTENSITY OF LIPID-LOWERING THERAPY, ADHERENCE AND LDL-CHOLESTEROL GOAL ATTAINMENT IN PATIENTS WITH CORONARY HEART DISEASE
    Mazhar, F.
    Hjemdahl, P.
    Clase, C. M.
    Johnel, K.
    Jernberg, T.
    Carrero, J. J.
    ATHEROSCLEROSIS, 2022, 355 : E301 - E301
12345